We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

ELITechGroup

Offers a range of products for in vitro diagnostics in clinical chemistry, hemostasis, microbiology, immunology, and ... read more Featured Products: More products

Download Mobile App




Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus

By LabMedica International staff writers
Posted on 29 Dec 2023
Print article
Image: Bruker has made two year-end acquisitions of ELITechGroup and Phasefocus (Photo courtesy of Bruker)
Image: Bruker has made two year-end acquisitions of ELITechGroup and Phasefocus (Photo courtesy of Bruker)

Bruker Corporation (Billerica, MA, USA), an international life science research and diagnostics solutions provider, has entered into separate agreements to acquire ELITechGroup (Puteaux, France), a global manufacturer of in-vitro diagnostics (IVD), and Phasefocus Holdings Limited (Sheffield, UK), a cell imaging company. The acquisitions are expected to strengthen Bruker’s position in molecular diagnostics and microscopy, respectively.

According to a Dec. 26 regulatory filing, Bruker will acquire ELITech for a purchase price derived from an enterprise value of USD 966.1 million, subject to certain adjustments. ELITech has been owned and operated by private equity firm PAI Partners (Paris, France) since 2017. ELITech specializes in developing and manufacturing IVD instruments and reagents and enjoys a strong market position in niche IVD segments in molecular diagnostics and microbiology. The company offers products to hospitals and laboratories for diagnosing diseases, identifying disease risk factors, and optimizing treatment choices. ELITech has undertaken transformative initiatives, such as R&D investments, the launch of next-generation molecular diagnostics systems, and new strategic partnerships for product development. These initiatives have strengthened ELITech’s competitive position and improved its reputation as an industry innovator, resulting in significant financial growth and profitability.

“Our partnership with PAI, together with the hard work and drive for innovation of our teams, have helped develop ELITech into the company that it is today,” said Christoph Gauer, CEO of ELITech Group. “It’s incredibly rewarding to see that our collective efforts have been a success and position us well for this exciting next chapter. I’d like to thank PAI for their support over the years and look forward to what the ELITech team can achieve as part of Bruker.”

In a separate transaction, Bruker has signed a definitive agreement to acquire Phasefocus, a privately held company with leading expertise in imaging and image processing algorithms. Financial details of the transaction were not disclosed. Phasefocus has developed a novel optical microscope, called Livecyte, for label-free imaging that is based on strong algorithms and patented technology. Phasefocus’ microscopy capabilities will enhance Bruker’s existing portfolio, enabling new research advances in a range of cell imaging applications while Bruker’s global reach will help build on Phasefocus’ success to date.

“Phasefocus has extensive image processing and algorithm expertise that they have nicely deployed in their Livecyte product,” said Dr. Frank Burgaezy, President AXS division. “This is a good addition to our broad imaging portfolio and their technology will enable us to drive further product developments.”

“We are very pleased to join Bruker,” added Dr. Martin Humphry, CEO of Phasefocus. “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our products for investigation of dynamic single cell behavior.”

Related Links:

Bruker Corporation
ELITechGroup
PAI Partners
Phasefocus Holdings Limited 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.